NeuBase Therapeutics, Inc. (“NeuBase” or the “Company”) announced the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer. At NeuBase, Dr. Rossomando will be responsible for manufacturing and process development, analytical development, and biophysical characterization in support of FDA regulatory submissions.